BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 32892843)

  • 1. Transfusion support for stem cell transplant recipients.
    Adkins BD; Booth GS; Vasu S
    Semin Hematol; 2020 Apr; 57(2):51-56. PubMed ID: 32892843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transfusion challenges in hematology oncology and hematopoietic stem cell transplant - Literature review and local experience.
    Elemary M; Seghatchian J; Stakiw J; Bosch M; Sabry W; Goubran H
    Transfus Apher Sci; 2017 Jun; 56(3):317-321. PubMed ID: 28642120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transfusion support for matched sibling allogeneic hematopoietic stem cell transplantation (1993-2010): factors that predict intensity and time to transfusion independence.
    Griffith LM; VanRaden M; Barrett AJ; Childs RW; Fowler DH; Kang EM; Tisdale JF; Klein HG; Stroncek DF
    Transfusion; 2019 Jan; 59(1):303-315. PubMed ID: 30362577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transfusion policy in allogeneic hematopoietic stem cell transplantation.
    Topcuoglu P
    Transfus Apher Sci; 2018 Apr; 57(2):174-177. PubMed ID: 29724631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is cytomegalovirus testing of blood products still needed for hematopoietic stem cell transplant recipients in the era of universal leukoreduction?
    Kekre N; Tokessy M; Mallick R; McDiarmid S; Huebsch L; Bredeson C; Allan D; Tay J; Tinmouth A; Sheppard D
    Biol Blood Marrow Transplant; 2013 Dec; 19(12):1719-24. PubMed ID: 24099958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complex Transfusion Issues in Pediatric Hematopoietic Stem Cell Transplantation.
    Webb J; Abraham A
    Transfus Med Rev; 2016 Oct; 30(4):202-8. PubMed ID: 27439965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unrelated donor stem cell transplantation for transfusion-dependent thalassemia.
    Shenoy S; Thompson AA
    Ann N Y Acad Sci; 2016 Mar; 1368(1):122-6. PubMed ID: 26999376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transfusional iron overload in patients receiving autologous stem cell transplantation: An underestimated problem requiring further consideration.
    Bauduer F; Recanzone H
    Transfus Apher Sci; 2020 Oct; 59(5):102837. PubMed ID: 32540346
    [No Abstract]   [Full Text] [Related]  

  • 9. Concluding commentary on current trends to enhance the clinical safety of pediatric transfusion, focusing on prevention of untoward complications of HSC transplantation & newer strategies for improving the standards of safety/quality of stem cells expansion for cellular therapy.
    Sniecinski I; Seghatchian J
    Transfus Apher Sci; 2018 Jun; 57(3):378-383. PubMed ID: 29778713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors influencing platelet transfusion refractoriness in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Solves P; Sanz J; Freiria C; Santiago M; Villalba A; Gómez I; Montesinos P; Montoro J; Piñana JL; Lorenzo JI; Puig N; Sanz GF; Sanz MÁ; Carpio N
    Ann Hematol; 2018 Jan; 97(1):161-167. PubMed ID: 29150812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of two protocols for platelet transfusion in patients undergoing abo incompatible hematopoietic stem cell transplantation.
    Solves P; Diaz Á; Carretero C; Gómez I; Carpio N; Sanz G
    Transfus Apher Sci; 2019 Apr; 58(2):185-186. PubMed ID: 30910618
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical factors affecting engraftment and transfusion needs in SCT: a single-center retrospective analysis.
    Liesveld J; Pawlowski J; Chen R; Hyrien O; Debolt J; Becker M; Phillips G; Chen Y
    Bone Marrow Transplant; 2013 May; 48(5):691-7. PubMed ID: 23085827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of leukocyte compatibility on neutrophil increment after transfusion of granulocyte colony-stimulating factor-mobilized prophylactic granulocyte transfusions and on clinical outcomes after stem cell transplantation.
    Adkins DR; Goodnough LT; Shenoy S; Brown R; Moellering J; Khoury H; Vij R; DiPersio J
    Blood; 2000 Jun; 95(11):3605-12. PubMed ID: 10828051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engraftment of early erythroid progenitors is not delayed after non-myeloablative major ABO-incompatible haematopoietic stem cell transplantation.
    Maciej Zaucha J; Mielcarek M; Takatu A; Little MT; Gooley T; Baker J; Maloney DG; Sandmaier BM; Maris M; Chauncey T; Storb R; Torok-Storb B
    Br J Haematol; 2002 Dec; 119(3):740-50. PubMed ID: 12437653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transfusion support issues in hematopoietic stem cell transplantation.
    Cohn CS
    Cancer Control; 2015 Jan; 22(1):52-9. PubMed ID: 25504279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Review of Growth Factor Support in Bloodless Autologous Hematopoietic Stem Cell Transplant.
    Zhao JC; Arnall JR; Martin AL; Atrash S; Bhutani M; Voorhees P; Avalos B; Copelan E; Ghosh N; Hamadani M; Usmani S; Ford P
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):e305-e309. PubMed ID: 31295572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depletion of donor-specific anti-HLA A2 alloantibodies in a hematopoietic cell transplant recipient using directed mismatched platelet transfusions.
    Spriewald BM; Bach C; Zingsem J; Strobel J; Winkler J; Mackensen A; Roesler W
    Bone Marrow Transplant; 2018 Jun; 53(6):791-794. PubMed ID: 29795430
    [No Abstract]   [Full Text] [Related]  

  • 18. A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation.
    Gajewski JL; Johnson VV; Sandler SG; Sayegh A; Klumpp TR
    Blood; 2008 Oct; 112(8):3036-47. PubMed ID: 18583566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diffuse alveolar hemorrhage is most often fatal and is affected by graft source, conditioning regimen toxicity, and engraftment kinetics.
    Keklik F; Alrawi EB; Cao Q; Bejanyan N; Rashidi A; Lazaryan A; Arndt P; Dincer EH; Bachanova V; Warlick ED; MacMillan ML; Arora M; Miller J; Brunstein CG; Weisdorf DJ; Ustun C
    Haematologica; 2018 Dec; 103(12):2109-2115. PubMed ID: 30076172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery.
    Green MM; Chao N; Chhabra S; Corbet K; Gasparetto C; Horwitz A; Li Z; Venkata JK; Long G; Mims A; Rizzieri D; Sarantopoulos S; Stuart R; Sung AD; Sullivan KM; Costa L; Horwitz M; Kang Y
    J Hematol Oncol; 2016 Aug; 9(1):71. PubMed ID: 27535663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.